热门资讯> 正文
上海君士，Coherus BioSciences合作伙伴将在美国和加拿大许可TIGIT靶向抗体
2022-01-11 18:16
05:12 AM EST, 01/11/2022 (MT Newswires) -- Shanghai Junshi Biosciences (HKG:1877) said Monday that Coherus BioSciences commenced the licensing of the former's TIGIT-targeted antibody, JS006, in the US and Canada.
As part of the immuno-oncology collaboration agreement, the US-based biologics platform company will pay Shanghai Junshi Biosciences an upfront amount of $35 million, up to $255 million in development regulatory and sales milestones and an 18% royalty on net product revenue.
Deal completion is subject to regulatory approvals.
Price (HKD): $44.65, Change: $+0.15, Percent Change: +0.34%
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
